{"id":"NCT02332590","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","officialTitle":"A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-28","primaryCompletion":"2016-01-20","completion":"2020-12-29","firstPosted":"2015-01-07","resultsPosted":"2017-07-25","lastUpdate":"2022-03-28"},"enrollment":369,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Sarilumab","otherNames":["SAR153191","REGN88"]},{"type":"DRUG","name":"Adalimumab","otherNames":["Humira"]},{"type":"DRUG","name":"Placebo (for sarilumab)","otherNames":[]},{"type":"DRUG","name":"Placebo (for adalimumab)","otherNames":[]}],"arms":[{"label":"Adalimumab 40 mg/Sarilumab 200 mg","type":"ACTIVE_COMPARATOR"},{"label":"Sarilumab 200 mg/Sarilumab 200 mg","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy with respect to signs and symptoms as assessed by disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) in participants with active rheumatoid arthritis (RA) who were either intolerant of, or considered inappropriate candidates for continued treatment with methotrexate (MTX), or after at least 12 weeks of continued treatment with MTX, were determined to be inadequate responders.\n\nSecondary Objectives:\n\nTo demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy in participants with active RA who were either intolerant of, or considered inappropriate candidates for continued treatment with MTX, or after at least 12 weeks of continued treatment with MTX, were determined to be inadequate responders, with respect to:\n\n* Reduction of signs and symptoms of RA.\n* Improvement in quality of life assessed by participant reported outcome questionnaires.\n\nAssessment of the safety and tolerability of sarilumab monotherapy (including immunogenicity) throughout the study.","primaryOutcome":{"measure":"DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Adalimumab 40 mg/Sarilumab 200 mg","deltaMin":-2.2,"sd":0.106},{"arm":"Sarilumab 200 mg/Sarilumab 200 mg","deltaMin":-3.28,"sd":0.105}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":86,"countries":["United States","Chile","Czechia","Germany","Hungary","Israel","Peru","Poland","Romania","Russia","South Africa","South Korea","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["36727470","36413080","36008838","34519964","33081825","32907617","32522251","32343882","32264972","31673415","30877216","27856432"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":184},"commonTop":["Nasopharyngitis","Neutropenia","Bronchitis","Accidental overdose","Injection site erythema"]}}